Journal of Pharmaceutical Investigation

  • 제33권1호
  • /
  • Pages.45-49
  • /
  • 2003
  • /
  • 2093-5552(pISSN)
  • /
  • 2093-6214(eISSN)
한국약제학회 (The Korean Society of Pharmaceutical Sciences and Technology)
권호 표지
DOI QR코드

DOI QR Code

용제 중 염산온단세트론의 용해성 및 안정성

Solubility and Physicochemical Stability of Ondansetron Hydrochloride in Various Vehicles

  • 곽혜선 (조선대학교 약학대학) ;
  • 오익상 (동덕여자대학교 약학대학) ;
  • 전인구 (동덕여자대학교 약학대학)
  • Gwak, Hye-Sun (College of Pharmacy, Chosun University) ;
  • Oh, Ik-Sang (College of Pharmacy, Dongduk Women's University) ;
  • Chun, In-Koo (College of Pharmacy, Dongduk Women's University)
  • 발행 : 2003.03.20
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The solubility and stability of ondansetron hydrochloride (OS) in various vehicles were determined. The effect of cyclodextrins (CD) on the solubility of OS in water was determined by equilibrium solubility method. The solubility of OS at $32^{\circ}C$ increased in the rank order of isopropyl myristate (IPM) < propylene glycol laurate (PGL) ${\ll}$ propylene glycol monolaurate < propylene glycol monocaprylate (PGMC) < poly(ethylene glycol) 400 < diethylene glycol mono ethyl ether (DGME) < ethanol < poly(ethylene glycol) 300 < water (36.1 mg/ml) ${\ll}$ propylene glycol (PG) (283 mg/ml). The addition of PG or DGME to non-aqueous vehicles such as IPM, PGL and PGMC markedly increased the solubility of OS. The addition of CDs in water increased the solubility. Apparent stability constant for the CD complexation with OS was calculated to be $25.5\;M^{-1}$ for $2-hydroxypropyl-{\beta}-CD\;(2HP{\beta}CD)$. Twenty mM ${\beta}-CD$, 69.4 mM sulfobutyl ether ${\beta}-CD$ and 115.4 mM $2HP{\beta}CD$ increased the aqueous solubilty of OS 1.27, 2.18 and 1.85 times, respectively. OS was stable in buffered aqueous solution (pH 5.0). However, OS was relatively unstable in non-aqueous vehicles in the order of PG

키워드

참고문헌

  1. L.X. Cubeddu, I.S. Hoffmann, N.T. Fuenmayor and A.L.Finn, Effcacy of ondansetron and the role of serotonin in cisplatin-induced nausea and vomiting, N. Engt. J. Med.,322, 810-816 (1990) https://doi.org/10.1056/NEJM199003223221204
  2. A. Khojasteh, G. Sartiano, E. Tapazoglou, E. Lester, D.Gandara, S. Bemard and A. Finn, Ondansetron of cisplatin-induced emesis, N. Engl J. Med., 322, 816-821 (1990) https://doi.org/10.1056/NEJM199003223221205
  3. M.G. Kris, R.J. Gralla, R.A. Clark, L.B. Tyson, J.P.O'Connell, M.S. Werthelm and D.P. Kelsen, Incidence,course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin, J. Clin.Oncol., 3, 1379-1384 (1985) https://doi.org/10.1200/JCO.1985.3.10.1379
  4. M.B. Tyers, K.T. Bunce and P.P.A. Humphrey, Pharma-cological and antiemetic properties of ondansetron, Eur. J.Cancer. Clin. Oncol., 25 (Suppl. 1), S15-S19 (1989)
  5. D.B. Smith, E.S. Newlands, G.J.S. Rustin, R.H.J. Begent, N.Howells, B. McQuade and K..D. Bagshawe, A phase/ studyof the 5-HTantagonist GR38032F in the anti-emetic prophy-laxis of patients receiving high-dose cisplatin chemotherapy,Cancer Chemother. Pharmacol.25, 291-294 (1990) https://doi.org/10.1007/BF00684888
  6. B. Costall, A.M. Domeney, S.J. Gunning, R.J. Naylor, F.D.Tattersall and M.B. Tyers, GR38032F, A potent and novelinhibitor of cisplatin-induced emesis in the ferret, Br. J.Pharmacol, (Proc. Suppl.), 90, 90P (1987)
  7. A. Butler, J.M. Hill, S.J. Ireland, C.C. Jordan and M.B.Tyers, Pharmacological properties of GR38032F, a novelantagonist at 5-HT3 receptors, Br. J. Pharmacol., 94, 397-412 (1988) https://doi.org/10.1111/j.1476-5381.1988.tb11542.x
  8. R.T. Britain, A. Butler, I.H. Coates, D.H. Fortune, R. Hagen, J.M. Hill, D.C. Humber, P.P.A. Humphrey, S.J. Ireland, D.Jack, C.C. Jordan, A. Oxford, D.W. Straughan and M.B.Tyers, GR38032F, a novel selective S-HTreceptor antagonist, Br. J. Pharmacol, 90, 87P (1987)
  9. M. koulu, B. Sjoholm, J. Lappalalnen and J. Hietala, Effects of acute GR38032F (ondansetron [sic]), a 5-HTre-ceptor antagonist on dopamine and serotoninmetabolism in metabolic and nigrostriatal dopaminergic neurons, Eur. J.Pharmacol, 169, 321-324 (1989) https://doi.org/10.1016/0014-2999(89)90031-9
  10. L.X. Cubeddu, I.S. Hoffnann, N.T. Fuenmayor and A.L. Finn, Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens, J. Clin. Oncol., 8, 1721-1727 (1990)
  11. J.W.M. Mackinnon and D.T. Collin, The chemistry of ondansetron, Eur. J. Cancer. Clin. Oncol., 25 (Suppl 1), S61 (1989)
  12. T. Higuchi and K.A. Connors, Phase solubility techniques, Adv.Anal. Chem. Instr., 4, 117-212 (1965)